Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Seeks Ways To Measure Impact Of Critical Path Initiative

Executive Summary

FDA is seeking input on how it can measure the effect of its Critical Path initiative, FDA Regulatory Counsel Lisa Rovin said

You may also be interested in...

Novartis Sets Out On The Critical Path; Will Others Follow?

Novartis' announcement of research collaborations with FDA is one of the first tangible outcomes of the agency's Critical Path initiative

Pharmacometrics Can Guide Further Trials, Minimize Risks – FDA Analysis

Pharmacometric analysis can be used to refine the design of further studies following failed clinical trials, according to an analysis by reviewers in FDA's Office of Clinical Pharmacology & Biopharmaceutics

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts